Chemotalk Newsletter

The Chemotalk Newsletter is published once a month, and contains an overview of news stories that relate to chemotherapy treatment for cancer, multiple sclerosis, rheumatoid arthritis, or for anyone who has received an organ transplant.

Sign up to receive the monthly
Chemotalk Newsletter, and bulletins
about important chemotherapy breakthroughs.
E-mail address:
Subscribe Unsubscribe
 
Chemotalk Newsletter, Vol. 117: February 1, 2018

February's news begins with...

MANY ELDERLY LUNG CANCER PATIENTS RECEIVE NO TREATMENT

By Mark L. Fuerst

Nearly two-thirds of older patients with stage III LUNG CANCER do not receive any treatment, according to a new study.

Although more than one-third of new lung cancers are diagnosed in patients age 75 years and older, elderly patients may not receive standard-of-care therapy for lung cancer‹concurrent chemotherapy and radiation‹due to their age, concerns about fragility, less willingness of patients to pursue aggressive therapy, or concerns over the usefulness of therapy for patients with competing risk factors.

To gain insights into how octogenarian and nonagenarian patients are treated and how they fare, researchers led by Richard J. Cassidy, MD, of the Winship Cancer Institute at Emory University in Atlanta, examined data on US patients age 80 years and older with stage III non­small-cell lung cancer from 2004 to 2013 who had complete treatment records available in the National Cancer Data Base (NCDB). The main goal of the study was to identify patient and tumor factors associated with receiving or not receiving standard therapy. The results were published in Cancer.

Of the total 12,641 patients (median age, 83 years) entered in the study, 7,921 (62.7%) received no therapy. Black race and living in a lower-educated census tract were linked with a 23% and 20% increased likelihood of not receiving care, respectively, while treatment at an academic center was associated with a 20% increased likelihood of receiving cancer-directed therapy. Male sex and improved comorbidity status were also associated with receiving some form of therapy.

Patients who received no treatment or only radiation were more likely to die during the years analyzed than those receiving the standard-of-care therapy.

"Our study is the largest to look at patients 80 years and older with stage III lung cancer. We highlight risks for patients not receiving standard therapy and show that patients who receive standard care live longer," said Cassidy. "Our study also highlights healthcare disparities in the oncology community and showcases a need for the oncology community to address. This may provide information to guide outreach programs to engage the elderly community in seeking appropriate therapy for stage III lung cancer."

Read more...

Vol 117: February, 2018

Vol 105: January, 2017

Vol 106: February, 2017

Vol 109: May, 2017

Vol 110: June, 2017

Vol 111: July, 2017

Vol 112: August, 2017

Vol 113: September, 2017

Vol 114: October, 2017

Vol 115: November, 2017

Vol 116: December, 2017

Vol 93: January, 2016

Vol. 94: February, 2016

Vol. 95: March, 2016

Vol. 96: April, 2016

Vol. 97: May, 2016

Vol. 98: June, 2016

Vol. 99: July, 2016

Vol. 100: August, 2016

Vol. 101: September, 2016

Vol. 102: October, 2016

Vol. 103: November, 2016

Vol. 104: December, 2016

Vol 81: January, 2015

Vol 82: February, 2015

Vol 83: March, 2015

Vol 84: April, 2015

Vol 85: May, 2015

Vol 86: June, 2015

Vol 87: July, 2015

Vol 88: August, 2015

Vol 89: September, 2015

Vol 90: October, 2015

Vol 91: November, 2015

Vol 92: December, 2015

Vol. 69: January, 2014

Vol 70: February, 2014

Vol 71: March, 2014

Vol 72: April, 2014

Vol 73: May, 2014

Vol 74: June, 2014

Vol 75: July, 2014

Vol 76: August, 2014

Vol 77: September, 2014

Vol 78: October, 2014

Vol 79: November, 2014

Vol 80: December, 2014

Vol 57: January, 2013

Vol 58: February, 2013

Vol 59: March, 2013

Vol. 60: April, 2013

Vol. 61: May, 2013

Vol. 62: June, 2013

Vol. 63: July, 2013

Vol. 64: August, 2013

Vol. 65: September, 2013

Vol. 66: October, 2013

Vol. 67: November, 2013

Vol. 68: December, 2013

Vol 56: December, 2012

Vol 55: November, 2012

Vol 54: October, 2012

Vol 53: September, 2012

Vol 52: August, 2012

Vol 51: July, 2012

Vol 50: June, 2012

Vol 49: May, 2012

Vol 48: April, 2012

Vol 47: March, 2012

Vol 46: February, 2012

Vol 45: January, 2012

Vol 44: December, 2011

Vol 43: November, 2011

Vol 42: October, 2011

Vol 41: September, 2011

Vol 40: August, 2011

Vol 39: July, 2011

Vol 38: June, 2011

Vol 37: May 1, 2011

Vol 36: April 1, 2011

Vol 35: March 1, 2011

Vol 34: February 1, 2011

Vol 33: January 1, 2011

Vol 32: December 1, 2010

Vol 31: November 1, 2010

Vol 30: October 1, 2010

Vol 29: September, 2010

Vol 28: August, 2010

Vol 27: July, 2010

Vol 26: June, 2010

Vol. 25: May, 2010

Vol. 24: April, 2010

Vol. 23: March, 2010

Vol. 22: February, 2010

Vol. 21: January, 2010

Vol. 20: December, 2009

Vol. 19: November, 2009

Vol. 18: October, 2009

Vol. 17: September, 2009

Vol. 16: August, 2009

Vol. 15: July, 2009

Vol. 13: June, 2009

Vol. 12: May, 2009

Vol. 11: April, 2009

Vol. 10: March, 2009

Vol. 9: February, 2009

Vol. 8: January, 2009

Vol. 7: December, 2008

Vol. 6: November, 2008

Vol. 5: October, 2008

Vol. 4: September, 2008

Vol. 3: August, 2008

Vol. 2:  July 1, 2008

Vol. 1:  June 1, 2008

 


Home | About Elaine | About the Book | Mission | ChemoTalk.com | Chemotalk Newsletter | Media Room |
Chemo Coaching | Speaking Engagements | Blog | Links | Contact